CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • November 8th, 2024 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of October 7, 2024, is entered into by and between Virios Therapeutics, Inc., a Delaware corporation (the “Company”), and Broadridge Corporation Issuer Solutions, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein).
FORM OF PURCHASER STOCKHOLDER SUPPORT AGREEMENT VIRIOS therapeutics, inc. SUPPORT AGREEMENTSupport Agreement • November 8th, 2024 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of October 7, 2024 (the “Effective Date”), is made by and between Virios Therapeutics, Inc., a Delaware corporation (“Purchaser”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Purchaser.
FORM OF REPURCHASE AGREEMENTRepurchase Agreement • November 8th, 2024 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This REPURCHASE AGREEMENT (this “Agreement”), dated as of [●] (the “Effective Date”), is made and entered into by and among SEALBOND LIMITED, a British Virgin Islands corporation (“Optionee”) and VIRIOS THERAPEUTICS, INC., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Share Exchange Agreement (as defined below) or the Certificate of Designation of Preferences Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (“Certificate of Designation”).
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • November 8th, 2024 • Dogwood Therapeutics, Inc. • Pharmaceutical preparations
Re:Share Exchange Agreement, dated as of October 7, 2024 (the “Exchange Agreement”), by and between Virios Therapeutics, Inc. (the “Company”) and Sealbond Limited (“Seller”)
